Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 127-131 , April 2000

Malignant thymoma: current status and future directions

References 

  1. Morgenthaler T, Brown L, Colby T. Thymoma. Mayo Clin Proc. 1993;68:1110–1123
  2. McKenna WG, Bonomi P, Barnes MM, Glatstein E. Malignancies of the thymus. In:  Roth JA,  Ruckdeschel JC,  Weisenburger TH editor. Thoracic oncology. Philadelphia, PA: WB Saunders Co; 1989;p. 466–477
  3. Fornasiero A, Daniele O, Ghiotto C. Chemotherapy of invasive thymoma. J Clin Oncol. 1990;8:1419–1423
  4. Wilkins EW, Grillo H, Scannell G. Role of staging in prognosis and management of thymoma. Ann Thorac Surg. 1991;51:888–892
  5. Halpern SR, Schoelzel E, Johnson RB. Thymoma in a young child producing symptoms of asthma. Am J Dis Child. 1966;111:99–104
  6. Pescarmona E, Rendina EA, Venuta F. Analysis of prognostic factors and clinicopathologic staging of thymoma. Ann Thorac Surg. 1990;50:534–538
  7. Blumberg D, Port J, Weksler B. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg. 1995;60:908–914
  8. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971;38:497–537
  9. Rosenow EC, Hurley BT. Disorders of the thymus: a review. Arch Intern Med. 1984;144:763–770
  10. McKenna WG, Bonomi PD, Barnes MM, Glatstein E. Malignancies of the thymus. In:  Roth JA,  Rucksdeschel JC,  Weisenburger TH editor. Thoracic Oncology. Philadelphia PA: WB Saunders; 1989;p. 466–477
  11. Muller-Hermelink HK, Marino M, Palestro G. Pathology of thymic epithelial tumors. Curr Topics Pathol. 1986;75:207–268
  12. Schneider PM, Fellbaum C, Fink U. Prognostic importance of histomorphic subclassification for epithelial thymic tumors. Ann Surg Oncol. 1997;4:46–56
  13. Masaoka A, Monden Y, Nakahara K. Follow-up study of thymoma with special reference to their clinical stages. Cancer. 1981;48:2485–2492
  14. Cooper JD. Current therapy for thymoma. Chest. 1993;103:334S–336S
  15. Tomiak EM, Evans WK. The role of chemotherapy in invasive thymoma: a review of the literature and considerations for future clinical trials. Crit Rev Oncol Hematol. 1993;15:113–124
  16. Loehrer PJ. Thymomas: curent experience and future directions in therapy. Drugs. 1993;45:477–487
  17. Fechner RE. Recurrence of non-invasive thymomas. Cancer. 1969;23:1423–1427
  18. Maggi G, Casadio C, Cavallo A. Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991;51:152–156
  19. Nakahara K, Ohno K, Hashimoto J. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovac Surg. 1988;95:1041–1047
  20. Curran WJ, Kornstein MJ, Brooks JJ, Turrisi AT. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6:1722–1727
  21. Lava N, Rodichok I, Martinez L. Recurrence of thymoma and myasthenia gravis after 19 years – a case report. Neurology. 1976;26:696–698
  22. Denayer MA, Rao KR, Wirz D, McNally D. Hepatic metastatic thymoma and myasthenia gravis twenty-two years after the apparent cure of an invasive thymoma. J Neurol Sci. 1986;76:23–30
  23. Ariaratnam L, Kalnicki S, Mincer F. The management of malignant thymoma with radiation therapy. Int J Radiat Oncol Biol Phys. 1979;5:77–80
  24. Haniuda M, Morimoto M, Nishimura H. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg. 1992;54:311–315
  25. Wang L, Huang M, Lin T. Malignant thymoma. Cancer. 1992;70:443–450
  26. Boston B. Chemotherapy of invasive thymoma. Cancer. 1976;38:49–52
  27. Bonomi PD, Finkelstein D, Aisner S. EST 2582: Phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol. 1993;16:342–345
  28. Highley MS, Underhill CR, Parnis FX. Treatment of invasive thymoma with single agent ifosfamide. J Clin Oncol. 1999;17:2737–2744
  29. Fornasiero A, Daniele O, Ghiotto C. Chemotherapy for invasive thymoma: a 13-year experience. Cancer. 1991;68:30–33
  30. Loehrer PJ, Kim K, Aisner S. Cisplatin plus doxorubicin plus cyclophophamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol. 1994;12:1164–1168
  31. Oshita F, Kasai T, Kurata T. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Jpn J Clin Oncol. 1995;25:208–212
  32. Giaccone G, Ardizoni A, Kirkpatrick A. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14:814–820
  33. Loehrer PJ, Jiroutek M, Aisner S. et al. Phase II trial of etoposide (V), ifosfamide (I), plus cisplatin (P) in patients with advanced thymoma (T) or thymic carcinoma (TC): preliminary results from an ECOG coordinated intergroup trial. Proc Am Soc Clin Oncol. 1998;17:118
  34. Palmieri G, Lastoria S, Montella L. Phase II study of somatostatin analogs and prednisone in chemotherapy-refractory thymoma patients. Proc Am Soc Clin Oncol. 1999;18:448a (#1730)
  35. Lara PN, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest. 1996;110:1115–1117
  36. Musi M, Di Vito F, Rosti G. Salvage chemotherapy for recurrent invasive thymoma (letter). Chest. 1997;112:572
  37. Gerbino A, Berutti A, Gorzegno G. Neoadjuvant chemotherapy with doxorubicin, cisplatin, vincristine and cyclophosphamide (ADOC) in locally advanced thymoma. Proc Am Soc Clin Oncol. 1998;17:1867

PII: S0305-7372(99)90159-7

doi: 10.1053/ctrv.1999.0159

Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 127-131 , April 2000

Article Tools